Microbot Medical Secures Patents in Multiple Global Jurisdictions

Medical Secures Patents in Multiple Global Jurisdictions

Mass., November 17, 2020 - Microbot Medical Inc. (Nasdaq: MBOT) announced that it has received patents in multiple jurisdictions,

further demonstrating the Company's continued execution of expanding and protecting its Intellectual Property (IP) portfolio.

The Company now has 40 issued/allowed patents and 23 patent applications pending worldwide.

we continue to make progress on the development, clinical and regulatory fronts, it is encouraging that we are also achieving

our goals to broaden the protection of our novel technologies," commented Harel Gadot, CEO, President and Chairman. "Strengthening

our IP portfolio is a critical component of Microbot's strategy for facilitating product evolution and maximizing future

commercial opportunities."

U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance 684 pertaining to the Company's Self-Cleaning Shunt

(SCS) device. The allowed patent application is a Continuation of a patent, issued on July 19, 2016, and covers a device for mitigating

occlusion in an implantable catheter. The claims are directed to a device comprising a tube having at least one drainage opening

disposed in its wall and configured for implantation within a body cavity, further comprising a cleaning element having at least

one cleaning protrusion extending into the opening and configured to move within the opening.

the European Patent Office (EPO) granted an EP Patent covering the Company's guidewire technology for use with endo-luminal

interventions, and related to the Company's LIBERTYTM development. This is the second European patent granted

for this unique technology and extends protection to include the device's current development, having a double guidewire

comprising a first hollow guidewire and a second guidewire deployed within the first guidewire, and an adjuster mechanism operable

to displace the second guidewire longitudinally relative to the first guidewire between at least three states.

Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,

focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological

platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes

for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical

is available at http://www.microbotmedical.com.

pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to

future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities

for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans,

or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation

Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to

statements that contain words such as "will," "believes," "plans," "anticipates,"

"expects" and "estimates") should also be considered to be forward-looking statements. Forward-looking

statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary

closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTYTM,

the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical

and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and

ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot

Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the

Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical disclaims

any intent or obligation to update these forward-looking statements, except as required by law.